 |
|
|
| |
A Phase 3 Study Comparing Switching From
Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide
With Continued TDF Treatment in Virologically Suppressed Patients With Chronic Hepatitis B:
Final Week 96 Efficacy and Safety Results
|
| |
| |
EASL 2020 Aug 27-29 virtual
Pietro Lampertico,1 Maria Buti,2 Alnoor Ramji,3 Scott Fung,4 Sang Hoon Ahn,5 Wan-Long Chuang,6 Seung Kew Yoon,7
Jia-Horng Kao,8 Chi-Yi Chen,9 Edward Tam,10 Mandana Khalili,11 Ho Bae,12 Xiaoli Ma,13 Won Young Tak,14 John F. Flaherty,15 Anuj Gaggar,15 Vithika Suri,15 Susanna K. Tan,15 George Wu,15 G. Mani Subramanian,15 Hie-Won Hann,16 Kosh Agarwal,17
Young-Suk Lim,18 Henry L.Y. Chan19
1Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Università di Milano, Milan, Italy; 2Hospital Universitari Vall d'Hebron, Barcelona, Spain; 3University of British Columbia, Vancouver, British Columbia, Canada; 4Toronto General Hospital, Toronto, Ontario, Canada; 5Yonsei University, Severance Hospital, Seoul, South Korea; 6Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung City, Taiwan; 7The Catholic University of Korea, Seoul, Korea; 8National Taiwan University Hospital, Taipei, Taiwan; 9Chia-Yi Christian Hospital, Chia-Yi City, Taiwan; 10LAIR Centre, Vancouver; 11University of California, San Francisco, California, USA; 12Saint Vincent Medical Center, Los Angeles, California, USA; 13Hahnemann University Hospital, Philadelphia, Pennsylvania, USA; 14Kyungpook National University Hospital, Daegu, South Korea; 15Gilead Sciences, Inc., Foster City, California; 16Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, USA; 17Kings College Hospital, London, UK; 18Asan Medical Center, Seoul; 19The Chinese University of Hong Kong, China
|
| |
|
|
|
|
|
